Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2024
2023
2022
2021
2020
2019

2021.03.16

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

2021.02.11

Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

2021.02.09

Adagene Inc. Announces Pricing of Initial Public Offering

2021.02.01

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

2021.01.12

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Pagination

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Next page
Last page

Displaying 66 - 70 of 79

Shareholder Tools

© 2024 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn